19 Jul Graftys closes 2M€ investment round to accelerate commercial development and new product launches

Posted at 09:57h in News by
0 Likes

Liege (Belgium), July 18, 2022 – GRAFTYS SA (“Graftys”), a recognized specialist in resorbable bone cements for orthopedic surgery, completed investment round of 2M€ with its existing shareholders. This round was mainly achieved with participation from GO CAPITAL via its West Venture 3 fund, from THE INNOVATION FUND, and NOSHAQ.

GRAFTYS SA is an innovative company based in Belgium with two operational subsidiaries in the south of France: GRAFTYS SAS in Aix en Provence and BIOLOGICS 4 LIFE in Pertuis. The company conceives, develops, and commercializes injectable biomaterials in more than 25 countries thanks to numerous regulatory approvals, most notably in Europe, US, and Brazil.

After completing a major restructure at all levels of the company along with relaunch of current products, GRAFTYS is developing new generations of products for market launch in 2023 and 2024. With the engagement of BIOLOGICS 4 LIFE, acquired in November 2021, the company now has robust resources for success in sales and innovation.

Directors Sebastien GENESTA and Xavier FERRY, and Aurelien VALET, President, thank our partners and appreciate their confidence in our team and our projects. “Completion of this investment round will facilitate our work to link GRAFTYS’ commercial performance with innovative capacity to provide important new technology for surgeons, across orthopedic and spine applications. We also remain committed to meeting the highest quality standards, which are always essential in the medical device industry.”

Bruno GUICHEUX, Director of Associated Investments at GO CAPITAL, adds: “The work achieved over the past few months by the new management team has been impressive and has positioned GRAFTYS as a high potential player in the bone cement market. These accomplishments have convinced GO CAPITAL to participate in this financing by addition of 1M€, thus reinforcing its position as a GRAFTYS investor.”


Press release
July 18, 2022
www.graftys.com
Copyright © 2021 Graftys. All rights reserved. Page | 2

About

GO CAPITAL


GO CAPITAL, an independent management company, is a key player in seed capital and risk capital in the regions. Based in Brittany, Pays de la Loire, Normandy, Centre Val de Loire and Région Sud, GO CAPITAL helps finance responsible innovation across the regions. Its team is made up of investors with complementary sectoral experience, and has a solid track record in deep tech. With more than 130 investments to its credit, GO CAPITAL manages more than €200M and mainly finances technology leaders in the digital, healthcare and future industry (energy transition, maritime economy, agri-agro, etc.) sectors.


More info : www.gocapital.fr


** The Innovation Fund


Created in February 2015, Innovation Fund invests in innovative startups and companies active in the field of chemistry and life sciences. The fund has a capital of €35m, financed by more than 50% by major companies in the sector, bringing unique industrial support value to the investment projects. The remaining 50% is held by national and regional investment funds, universities, banks and individuals. To date, the Innovation Fund has already invested in 352 companies.

More info: http://www.innovationfund.eu


*** Noshaq


Noshaq is an investment fund with a portfolio of 474 companies, including over 85 companies in the life sciences. Noshaq is the reference financial partner for the creation and development of SMEs in the Liège region. Over the years, Noshaq has developed a range of financing vehicles, which are suited to market needs and trends, as well as its strategy. Every service provided by Noshaq (capital – loans – leasing) is always designed according to the requirements and needs of the owner-investor. The aim is always to have a lever effect on the company’s development.


https://www.noshaq.be/


Press Contacts
Graftys and Biologics4Life : Aurélien VALET – General Manager of the Graftys Group – +33 6 27 46 22 15
USA : Ron Lowell, Business Development +1 847 651 3723
GO CAPITAL : Bruno GUICHEUX – Investment Director – +33 6 84 98 58 96
The Innovation Fund : André OSTACHKOV – Investment Director – +32 499 67 47 04
Noshaq : Benoit FELLIN – Investment Director – +32 473 84 11 59

SOURCE: Graftys, July 18 2022.

To find out more news from the industry head over to our news section – orthocg.com/news